LCT updates Diabecell trial
Wednesday, 11 February, 2009
Auckland’s Living Cell Technologies (LCT) has reported long-term follow-up results from seven patients implanted with its porcine islet product Diabecell in a Phase I/IIa trial in Russia.
Five patients who received double low-dose implants showed no safety concerns and maintained good blood glucose control. The other two patients on a single higher-dose implant also reported no safety concerns, the company said.
LCT’s medical director Professor Bob Elliott said none of the patients had problems with clinically relevant episodes of low blood glucose.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
